JP2018046826A5 - - Google Patents

Download PDF

Info

Publication number
JP2018046826A5
JP2018046826A5 JP2017195118A JP2017195118A JP2018046826A5 JP 2018046826 A5 JP2018046826 A5 JP 2018046826A5 JP 2017195118 A JP2017195118 A JP 2017195118A JP 2017195118 A JP2017195118 A JP 2017195118A JP 2018046826 A5 JP2018046826 A5 JP 2018046826A5
Authority
JP
Japan
Prior art keywords
alzheimer
disease
expression level
subject
matrigel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017195118A
Other languages
English (en)
Japanese (ja)
Other versions
JP6636488B2 (ja
JP2018046826A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018046826A publication Critical patent/JP2018046826A/ja
Publication of JP2018046826A5 publication Critical patent/JP2018046826A5/ja
Application granted granted Critical
Publication of JP6636488B2 publication Critical patent/JP6636488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017195118A 2011-10-05 2017-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー Active JP6636488B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543416P 2011-10-05 2011-10-05
US61/543,416 2011-10-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014534811A Division JP2014528247A (ja) 2011-10-05 2012-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー

Publications (3)

Publication Number Publication Date
JP2018046826A JP2018046826A (ja) 2018-03-29
JP2018046826A5 true JP2018046826A5 (enExample) 2018-07-26
JP6636488B2 JP6636488B2 (ja) 2020-01-29

Family

ID=47116384

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014534811A Pending JP2014528247A (ja) 2011-10-05 2012-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー
JP2017195118A Active JP6636488B2 (ja) 2011-10-05 2017-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014534811A Pending JP2014528247A (ja) 2011-10-05 2012-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー

Country Status (5)

Country Link
US (1) US20140235496A1 (enExample)
EP (1) EP2764120B1 (enExample)
JP (2) JP2014528247A (enExample)
CA (1) CA2861668C (enExample)
WO (1) WO2013052922A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103495A1 (en) * 2014-01-03 2015-07-09 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease
CN105353135A (zh) * 2015-11-23 2016-02-24 中国人民解放军第三军医大学第一附属医院 阿尔茨海默病标志物的用途
WO2017117333A1 (en) * 2015-12-30 2017-07-06 Cellular Dynamics International, Inc. Microtissue formation using stem cell-derived human hepatocytes
WO2018183703A1 (en) 2017-03-31 2018-10-04 NeuroDiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
US20210033628A1 (en) * 2018-04-30 2021-02-04 Cedars-Sinai Medical Center Diagnostic and drug screening for molecular signatures of early onset sporadic parkinson's disease
WO2022132856A1 (en) * 2020-12-16 2022-06-23 Synaptogenix, Inc. Treatment of amyotrophic lateral sclerosis using pkc activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
AU719038B2 (en) * 1996-03-29 2000-05-04 Trustees Of Boston University Methods for diagnosing and treating Alzheimer's disease
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
EP1934618B1 (en) 2005-10-11 2009-05-13 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US20080058396A1 (en) 2006-07-28 2008-03-06 Alkon Daniel L Methods of stimulating cellular growth, synaptic remodelling and consolidation of long-term memory
WO2008077094A2 (en) * 2006-12-19 2008-06-26 Children's Medical Center Corporation Methods for promoting neovascularization
EP3586839A1 (en) 2008-07-28 2020-01-01 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
JP2011529344A (ja) * 2008-07-28 2011-12-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の刺激誘発ゲノムプロフィールマーカー
KR101054725B1 (ko) * 2008-07-31 2011-08-05 재단법인서울대학교산학협력재단 세포외기질 성분을 함유하는 노화조절용 조성물 및 이를이용한 노화세포의 노화조절방법
EP2483684B1 (en) * 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Fibroblast growth patterns to diagnose alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2025069171A (ja) 急性呼吸器感染症を診断および処置するための方法
Miyake et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters
Angebault et al. Combined bacterial and fungal intestinal microbiota analyses: Impact of storage conditions and DNA extraction protocols
JP2015154774A5 (enExample)
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
BRPI0607753A2 (pt) método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml
WO2007011412A3 (en) Diagnosis and prognosis of infectious diesease clinical phenotypes and other physiologic states using host gene expresion biomarkers in blood
CN108348166B (zh) 用于与抗生素使用相关的感染性疾病及其它健康状况的源自微生物群系的诊断及治疗方法和系统
CN108350510A (zh) 用于胃肠健康相关病症的源自微生物群系的诊断及治疗方法和系统
JP2019520042A5 (enExample)
Bouquet et al. Whole blood human transcriptome and virome analysis of ME/CFS patients experiencing post-exertional malaise following cardiopulmonary exercise testing
JP2019528081A5 (enExample)
CA2791464A1 (en) Method of diagnosis of obesity
WO2012080754A3 (en) Oligonucleotide probe set and methods of microbiota profiling
JP2019510473A5 (enExample)
US20230017064A1 (en) Methods for the characterization of fluid
JP2013503617A5 (enExample)
JP6485843B2 (ja) 関節リウマチのバイオマーカー及びその使用
JP2018504909A5 (enExample)
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
Rowley Can a systems biology approach unlock the mysteries of Kawasaki disease?
Sofia de Olazarra et al. Rapid, Point-of-Care Host-Based Gene Expression Diagnostics Using Giant Magnetoresistive Biosensors
JP2020178555A5 (enExample)
JP2020178586A5 (enExample)
JP2020174639A5 (enExample)